Earnings Labs

American Vanguard Corporation (AVD)

Q3 2015 Earnings Call· Mon, Nov 2, 2015

$2.82

-1.05%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

+13.51%

1 Week

+7.42%

1 Month

+11.43%

vs S&P

+13.70%

Transcript

Operator

Operator

Greetings and welcome to the American Vanguard Corporation Third Quarter 2015 Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Bill Kuser, Director of Investor Relations. Thank you, sir. You may begin.

William Kuser

Analyst

Thank you very much, Adam, and welcome, everyone, to American Vanguard’s third quarter and nine-month earnings review. Our speakers today will be Mr. Eric Wintemute, the Chairman and CEO of American Vanguard; and Mr. David Johnson, the company’s Chief Financial Officer. We also have Mr. Bob Trogele, AMVAC’s Chief Operating Officer, available to answer some of your questions. Before beginning, let’s take a moment to review our usual cautionary reminder. In today’s call, the company may discuss forward-looking information. Such information and statements are based on estimates and assumptions by the company’s management, and are subject to various risks and uncertainties that may cause actual results to differ from management’s current expectations. Such factors can include weather conditions, changes in regulatory policy, competitive pressures, and various other risks that are detailed in the company’s SEC reports and filings. All forward-looking statements represent the company’s best judgment as of the date of this call and such information will not necessarily be updated by the company. With that said, we turn the call over to Eric.

Eric Wintemute

Analyst

Thank you, Bill, and thank you all for joining us this afternoon. We appreciate your interest in and support for American Vanguard. As we pointed out in our press release, American Vanguard’s third quarter and nine-month financial results reflect management’s focused efforts to improve profitability despite a challenging ag industry condition that have existed this year. First, I’ll provide some insights on our sales performance. Then, David will provide further color on our overall financial performance. I will finish our prepared remarks with comments on several initiatives that we believe will enhance our future growth and profitability, including the opportunities that we see in light of industry consolidation. With regard to sales, soft domestic ag market demand has been widely reported by industry analysts and most of our peers. Many factors have contributed to this condition, including low crop commodity prices, which have prompted growers to be somewhat more conservative when purchasing in an effort to manage their input cost; surplus inventory in the Midwest distribution channel, which has dampened the restocking procurement but is now getting down to traditional levels; and below average pest pressure, particularly in foliar insects that feast on corn higher than cotton. In light of these factors, we experienced lower quarterly sales of our corn and cotton products. We believe that with respect to corn, this result is largely a matter of timing, as the distribution channel maintains close control on procurement. Cotton products sales, as I mentioned, are driven by lower pest pressure and reduced acreage. By contrast, sales into other core markets such as potatoes, peanuts, vegetables, fruits, and international business collectively grew by 30% when compared to the third quarter of 2014. This includes growth in net sales of soil fumigants, Thimet® and Counter® soil insecticide, international sales of Mocap® and Nemacur®, with the addition of the European Nemacur registrations that we acquired in April; this Impact® corn herbicide and Dibrom® mosquito adulticide. These many positive factors contributed to a slight increase over the prior year’s third quarter net sales revenue. We also reported increased profitability on these revenues through our efforts to control operating expenses and factory cost. I will now ask David to expand upon this. David?

David Johnson

Analyst

Thank you, Eric. From my perspective, the financial issues of paramount importance to investors remain consistent with the last several quarters, and are factory utilization, operating expenses, inventory levels, margin performance and profitability, liquidity, and finally, interest and tax. On the first subject, factory performance, we had a strong performance in the third quarter in comparison to last year. Our factory costs were down about $2.5 million, primarily as a result of ongoing cost reduction and control efforts. Furthermore, we have managed our manufacturing carefully during the year and we’re able to increase output activity and overhead recovery by about 16% in the quarter as compared to this time last year. Taken together, this resulted in reducing our factory under-absorption expense by about $4.2 million compared to the third quarter of last year. The first nine months of the year continued to go well. So far, we have recorded under-absorption costs of $11 million, which is about a 47% improvement on last year. Looking forward, we mentioned in the press release that as we manage the manufacturing inventory/supply equation to the end the year, we do plan to have reduced factory utilization in the final quarter. We will, of course, continue to exercise a stringent cost control which has served us well in this third quarter and for the year-to-date. Second, with respect to operating expenses, in Q3 of 2015, we ended at $26.1 million as compared to $27.4 million for the same period of the prior year, an improvement of 5%. Overall, our focus is on controlling costs across all of our OpEx categories, while allowing the long term projects to proceed. On a year-to-date basis, we continued to achieve the goal which we set for ourselves, that is to keep our OpEx spending at or below the 2014…

Eric Wintemute

Analyst

Thank you, David. Now, let me make a few comments on our future. First, we believe that our success in corn will continue to be driven by the positive return that our proven yield-enhancing products provide to growers. We’re pleased to announce that we are launching two new products this current quarter, fourth quarter, Aztec 9.34 in SmartBox and Aztec 4.67 in bags. These concentrated versions of AMVAC’s industry-leading granular soil insecticides will provide the economics and ease of use that growers find appealing. Additionally, we will begin to see benefit from our co-marketing agreement with DuPont and other seed companies that will incentivize growers to use our soil insecticide with trait seed. Again this year, our impact of post-emergence herbicide will be co-marketed with Monsanto’s Roundup incentive program to compat the increasing proliferation of glyphosate-resistant weeds. In summary, we are expanding our corn franchise. Second, our traditional business model of product acquisition and product licensing is alive and well. In April, we announced product acquisitions for DuPont and Adama that should increase our international business by 25%. Just today, we announced a licensing agreement with BASF, for a corn herbicide product line that is used in both soybean and turf applications. Further, there has been a great deal of consolidation within the industry and more is expected. From this activity, we expect to see robust acquisition opportunities in the near and mid-term. These opportunities in turn play directly into our business model of expanding our portfolio through acquiring and licensing proven branded products. Third, our product development efforts continue at full throttle with a number of projects designed to drive our proprietary SmartBox equipment technology to the next level. Our unique SIMPAS technology is intended to provide a single-pass multi-functional planting treatment that could put us at the forefront…

Operator

Operator

[Operator Instructions] Our first question comes from the line of Jim Sheehan with SunTrust Robinson Humphrey.

Matthew Stevenson

Analyst

This is Matthew Stevenson on for Jim. Question about pre-season sales, a competitor of yours has talked extensively recently about limiting discounted pre-season sales in North American channels. Can you comment on whether you guys are seeing similar things or what motivation your pre-season selling strategy is?

Eric Wintemute

Analyst

In the third quarter and years past, we’ve seen some robust sales. I think a lot of it is having to do with supply availability than years 2011, 2012, 2013 and I think we’ve scaled that back both from our own standpoint making sure, of course, we’re working through inventory challenges, but also from a customer standpoint of wanting to keep their inventories under control. So happy to hear that others are in that same thought process because we think it bodes well for the industry overall.

Operator

Operator

Our next question comes from the line of Tyler Etten with Piper Jaffray.

Tyler Etten

Analyst · Piper Jaffray.

I was wondering if you could talk about channel inventories, what your confidence is in reaching the end of goal or end of your goal and what kind of demand we’d have to see in the market to do that, considering we saw delayed channel work down last year?

Eric Wintemute

Analyst · Piper Jaffray.

The channel inventory, I think, David mentioned is down 40% year-over-year. We still have some overage and maybe at that 40% when we might – would zeroing out might be closer to 25%. But we feel retail, the distributor level retail we think is perfectly in line. As far as outlook for the upcoming year, we’re not forecasting an increase in demand. We have done some market surveying and based on those surveys there seems to be some optimism that there will be increases, but we’re not looking at that at this point and certainly have inventory if that were the case. But I think we’re focusing on launching our two new products into that market and we’re optimistic about the outlook overall.

Tyler Etten

Analyst · Piper Jaffray.

On the debt raise, I was wondering if extra capital is going to be used for additional product lines specifically.

David Johnson

Analyst · Piper Jaffray.

That would be, I think, the target used for the proceeds at this point. I think we got our initiatives underway. I think we’re going to be prudent with capital investment and spending. I think we feel pretty good with where our plans are today and the money that we put into them in the past. So now, that would largely be targeted for those type of initiatives.

Tyler Etten

Analyst · Piper Jaffray.

We saw a nice lift in operating margin for the quarter. I was wondering if we could expect something like that going forward or if there was something specific in the quarter that drove that lift in operating margins?

David Johnson

Analyst · Piper Jaffray.

I think I explained it in my remarks that we had a very good factory performance in the quarter. We do expect to see higher on the utilization of the factory in the fourth quarter as we manage our way towards the target of $140 million in inventory. So we expect our margins to be a little down in the fourth quarter. When it comes to next year, we’re anticipating a further improvement in the recovery performance.

Tyler Etten

Analyst · Piper Jaffray.

One last question from me, if I can, and then I’ll get back in line. I noticed that the revenue comps were lifted as before the acquisitions earlier this year. I was wondering how much the acquisitions contributed to the revenue and margin to get a better idea on what comps were from existing products?

David Johnson

Analyst · Piper Jaffray.

I don’t have that specifically, but we acquired these assets mid-year and so there were inventory in the channels that resulted more in royalty-type commission rather than the full revenue recognition that we would have that we believe will be coming into play a little bit in the fourth quarter, but honestly full year next year, which is what I think. So I think you’ve got a relatively smaller number of revenue, but the revenue that’s there is pretty much margin.

Tyler Etten

Analyst · Piper Jaffray.

I guess the total is about $1.5 million number in total?

David Johnson

Analyst · Piper Jaffray.

As of this point, through the third quarter.

Operator

Operator

Our next question comes from the line of Chris Kapsch with BB&T Capital Management.

Christopher Kapsch

Analyst · BB&T Capital Management.

Just a follow-up on the question about channel inventories, you said you think that channel inventories are normal, but I’m just wondering what’s normal, there is some notion that maybe going forward, at least in this backdrop, a difficult backdrop, maybe the channel, once the – can afford to run their businesses at inventory levels below what’s been normal in the past just because of the abundant availability of products. So just wondering what your – based on your formal comments in terms of – what’s really normal for channel inventories? What’s your assumption looking forward?

Eric Wintemute

Analyst · BB&T Capital Management.

I think what I said was that we were at about 40% in-channel and that normal was closer to 25%. You’re maybe right that distribution may try to drive that down to 20%, but there is a lot of locations right across the Midwest and it’s not real easy. When we talk with distribution and they talk about numbers they would like to see, ideal would be close to that 20%, but I think particularly in light of the fact that we’ll be introducing couple of new skews that might be a little more difficult to accomplish.

Christopher Kapsch

Analyst · BB&T Capital Management.

And then just on the comments about your strategy in terms of growth either via product acquisition or in-licensing and considering the industry consolidation that’s taking place, just want a couple of things. One, based on your financial position, do you have a sense for what your capacity is to do product acquisitions or in-licensing? And then secondly, just the economics of any such deal, are they changing? I mean, a few years ago, obviously these deals were getting more expensive and now with the consolidation that’s taking place and given the lackluster backdrop, has that affected the economics for a buyer like yourselves of potential acquisition targets?

Eric Wintemute

Analyst · BB&T Capital Management.

As far as available, banks have always been there for us when we’ve come in and said, hey, we’d like to borrowing and we’ve got 25-plus year relationship there. And we think we’re not a leverage company, if you look at our debt to equity ratio. So I think we’ve got plenty of capacity depending on what comes our way. As far as the cost and multiples that we’re looking at, I think we’re seeing some softening that we are pleased with. We’ve had some fairly expensive deals that we’ve passed over in the previous years and I think we’re feeling relatively confident that there is going to be enough products on the market that will be plenty of opportunities for us.

Christopher Kapsch

Analyst · BB&T Capital Management.

Just to follow-up, Eric, if you could, I don’t know, provide anymore parameters around this in-licensing that you announced with BASF. Couple of things, any sense for what the annual revenues might be associated with this product and then also just BASF’s willingness to partner with this product. I mean, looking forward to either 2016 or maybe 2017, with probably 2016 it’s expected that the soybean world dicamba-tolerant trait will be approved and so that – seeds with dicamba-tolerant will be introduced to the market and therefore there’s going to be more use of dicamba herbicide, obviously BASF is a player there. So that may have some effect in their willingness to not focus on another alternative herbicide like this one. So just wondering if you could provide any color around the dynamic there, either putting to parameters around the – quantifying the sales associated with this product and their willingness to partner with it.

Eric Wintemute

Analyst · BB&T Capital Management.

This is a product that one time had sales north of $100 million and it certainly has decreased dramatically, I think last year is probably less than $5 million. Their focus is clearly not here; our focus will be in this area. We think there is a good fit for it in the southern corn markets. We’re also putting what we consider as some strong effort behind the turf market as well. We might look for some combination products that we could build upon this molecule with. So we’re excited to have this opportunity to work with this and again it’s a small product, we think we’ve got an opportunity to find some expansion in niche markets as we move forward.

Operator

Operator

[Operator Instructions] Our next question is a follow-up question from the line of Tyler Etten with Piper Jaffray.

Tyler Etten

Analyst

I was just wondering if you could provide some color on the cotton market. Obviously, we had a difficult year this year. Any read through on customers returning to the market next year, any acreage expectations if pricing is going to affect it, any information would help.

Bob Trogele

Analyst

We expect the cotton acreage for next year in the US to be flat year-on-year. This is mainly driven by China having a one-year inventory and the current price for cotton. So we expect the business to be dependent on pest pressure and our defoliation business to be flat year-on-year. We did launch some new defoliation products this year into the market which we expect to grow slightly next year.

Operator

Operator

Our next question is a follow-up from the line of Chris Kapsch with BB&T Capital Markets.

Christopher Kapsch

Analyst

Just on the factory utilization, I think your prepared comments suggested that you’d be – the utilization be curtailed sharply in the fourth quarter, but can you just talk about any early sense of what you might be thinking about in terms of 2016. And then other question was just aside to that, I guess, is with the inventories having come down a little bit, just wondering as you look through to 2016, any sense for how much of an opportunity inventories and/or working capital more generally might be in terms of source of cash and what the order of magnitude might be there assuming there is an opportunity in 2016.

David Johnson

Analyst

We’re anticipating for the full year about $18 million cost of under absorption and we’re expecting to improve that about 20% in 2016. We’re making sure that focus on managing our inventory down [indiscernible] levels that we’ve talked about at the end of this current year and we expect to see some reduction in inventory in 2016 as well.

Operator

Operator

Our next question comes from the line of [Bruce Winter] a private investor.

Unidentified Analyst

Analyst

News like the 30% increase of your non-corn and non-cotton crops, your strong cash flow, your margin, everything looks pretty good. My only question is why was today’s new product announcement, so why a licensing agreement when you usually do product acquisitions?

Eric Wintemute

Analyst

BASF has markets outside of the US and I think US and Canada or just US, US, yes, has markets outside of that. So they’re maintaining a relative availability to sell that product in other markets. Our license is for the US market.

Operator

Operator

[Operator Instructions] Ladies and gentlemen, there are no further questions at this time. I would now like to turn the floor back over to management for closing remarks.

Eric Wintemute

Analyst

Okay. I would like to thank everybody for joining us this afternoon. We look forward to reporting our year-end results towards the end of February, first of March. And appreciate all your support. Thank you.

Operator

Operator

Thank you. Ladies and gentlemen, this does conclude our teleconference for today. You may now disconnect your lines at this time. Thank you for your participation. Have a wonderful day.